Recent Finacing
Recent Raise
PTC Therapeutics develops orally administered small-molecule drugs targeting post-transcriptional control, advancing lead candidate ataluren for nonsense‑mutation genetic disorders and programs in oncology and infectious diseases.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
